Edition:
United States

Roche Holding AG (ROG.S)

ROG.S on Virt-X Level 1

235.05CHF
20 Sep 2018
Change (% chg)

-- (--)
Prev Close
CHF235.05
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,529,031
52-wk High
CHF252.85
52-wk Low
CHF206.35

Select another date:

Fri, Sep 14 2018

RPT-FOCUS-Roche steps up efficiency drive to take sting out of biosimilars

LONDON/ZURICH, Sept 13 Roche, the world's biggest producer of cancer drugs, is stepping up cost cuts in an efficiency drive made unavoidable by competition from cut-price copies of three mega-brands from its famed U.S. Genentech biotech stable.

Roche steps up efficiency drive to take sting out of biosimilars

LONDON/ZURICH Roche , the world's biggest producer of cancer drugs, is stepping up cost cuts in an efficiency drive made unavoidable by competition from cut-price copies of three mega-brands from its famed U.S. Genentech biotech stable.

FOCUS-Roche steps up efficiency drive to take sting out of biosimilars

LONDON/ZURICH, Sept 13 Roche, the world's biggest producer of cancer drugs, is stepping up cost cuts in an efficiency drive made unavoidable by competition from cut-price copies of three mega-brands from its famed U.S. Genentech biotech stable.

Roche boss says Brexit and curbs on drug use pose threat to UK science

LONDON Uncertainty over drug regulation and a reluctance by Britain's health service to use certain pricey modern medicines pose a threat to the country's respected life sciences sector, the head Swiss drugmaker Roche said on Thursday.

Roche boss says Brexit and curbs on drug use pose threat to UK science

LONDON Uncertainty over drug regulation and a reluctance by Britain's health service to use certain pricey modern medicines pose a threat to the country's respected life sciences sector, the head Swiss drugmaker Roche said on Thursday.

Roche boss says Brexit and curbs on drug use pose threat to UK science

LONDON, Sept 13 Uncertainty over drug regulation and a reluctance by Britain's health service to use certain pricey modern medicines pose a threat to the country's respected life sciences sector, the head Swiss drugmaker Roche said on Thursday.

BRIEF-Herceptin (Trastuzumab) Subcutaneous (SC) Formulation Approved In Canada For Treatment Of Her2-Positive Breast Cancer

* HERCEPTIN® (TRASTUZUMAB) SUBCUTANEOUS (SC) FORMULATION APPROVED IN CANADA FOR TREATMENT OF HER2-POSITIVE BREAST CANCER Source text for Eikon: Further company coverage:

Roche faces UK pricing row over multiple sclerosis drug Ocrevus

LONDON Roche faces a fresh row over drug pricing in Britain, following a decision by the body responsible for medicine use within the state health service not to approve its drug Ocrevus for treating a highly disabling form of multiple sclerosis (MS).

Roche faces UK pricing row over multiple sclerosis drug Ocrevus

LONDON, Sept 10 Roche faces a fresh row over drug pricing in Britain, following a decision by the body responsible for medicine use within the state health service not to approve its drug Ocrevus for treating a highly disabling form of multiple sclerosis (MS).

FDA extends review of Roche's Tecentriq by three months

ZURICH Roche said on Thursday the U.S. Food and Drug Administration (FDA) had extended by three months the review period for Tecentriq in combination therapy as a first-line treatment for a form of lung cancer.

Select another date: